Bill > HB228

This bill, the "Right to Try Act," aims to provide eligible patients with advanced illnesses access to investigational drugs, biological products, or devices that have completed phase one of a clinical trial but are not yet approved by the FDA. Key provisions of the bill include: 1. Defining an "eligible patient" as someone with an advanced illness, who has considered all other FDA-approved treatment options, is ineligible or unable to participate in a clinical trial, and has received a recommendation from their physician for an investigational product. 2. Allowing manufacturers to provide investigational products to eligible patients, either for free or by requiring the patient to pay the associated costs. 3. Clarifying that the bill does not expand insurance coverage requirements or require government agencies or healthcare facilities to pay for or provide the investigational products. 4. Protecting healthcare providers from professional discipline based solely on their recommendation of an investigational product to an eligible patient. 5. Prohibiting state officials from blocking an eligible patient's access to an investigational product. 6. Limiting civil liability for manufacturers and others involved in the care of eligible patients using the investigational products, as long as they comply with the Act and exercise reasonable care.

Budget and Finance, Justice

https://www.nmlegis.gov/Legislation/Legislation?chamber=H&legtype=B&legno=228&year=17